Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease.
about
Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week studyIpratropium bromide for stable chronic obstructive pulmonary diseaseLong-acting beta2-agonists for chronic obstructive pulmonary diseaseLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisCombined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary diseaseIpratropium bromide for stable chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary diseaseLong-acting beta2-agonists for poorly reversible chronic obstructive pulmonary diseaseIpratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary diseaseCombined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary diseaseLong acting beta2 agonists for stable chronic obstructive pulmonary disease with poor reversibility: a systematic review of randomised controlled trialsEfficacy and safety of conventional long acting β2- agonists: systematic review and meta-analysisCombination bronchodilator therapy in the management of chronic obstructive pulmonary diseaseCOPD exacerbations. 4: PreventionCopd.Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 updatePneumocafé project: an inquiry on current COPD diagnosis and management among General Practitioners in Italy through a novel tool for professional education.Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.Efficacy and safety of inhaled formoterol 4.5 and 9 μg twice daily in Japanese and European COPD patients: phase III study resultsEfficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysisCOPD: maximization of bronchodilation.Chronic obstructive pulmonary disease, pollution, pulmonary vascular disease, transplantation, pleural disease, and lung cancer in AJRCCM 2001.Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review.Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease.Long-acting inhaled beta 2-agonists for stable COPD.Obesity and COPD: associated symptoms, health-related quality of life, and medication useEarly onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004.Pharmacologic treatment of chronic obstructive pulmonary disease: past, present, and future.Formoterol: a review of its use in chronic obstructive pulmonary disease.Chronic obstructive pulmonary disease and community-based pharmacological care.Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials.FEV1 reversibility does not adequately predict effect of formoterol via Aerolizer in chronic obstructive pulmonary disease.Maintenance pharmacotherapy of chronic obstructive pulmonary disease: an evidence-based approach.The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD.GFF MDI for the improvement of lung function in COPD - A look at the PINNACLE-1 and PINNACLE-2 data and beyond.Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities.Optimizing safety of COPD treatments: role of the nurse practitioner.Systemic and bronchodilator effects of inhaled rac-formoterol in subjects with chronic obstructive pulmonary disease: a dose-response study.Pharmacotherapies for COPD.
P2860
Q21257191-7B27BEA3-7C84-4CCE-9D2E-5EB1D8E483A2Q24194933-567CEE0C-0FD7-439A-A3D5-F2E3F8664427Q24197467-BC2D82A8-53A5-499C-935E-95208BF0D077Q24197853-EBED38CB-95C7-4836-93C3-E931CAB4B346Q24200446-DCDA4B9B-852B-4FD9-A939-2C0B5DE52940Q24234151-DBB53011-A167-4DDD-9303-9ED9D8DE8659Q24243564-DC9A2287-AC4B-4B71-AA46-56649AA14974Q24245141-D060896D-79F8-4D44-9F67-5C5B15E6829EQ24245413-C8128F06-EB0B-4B28-9443-A579643DCAEFQ24246591-0515BF7C-6686-4C93-A16C-49342E75A18DQ24792685-4F0E2587-CD06-4F49-8079-F05222BA6CB8Q26744161-2E83EA11-32DD-445D-9A4A-75AFDC5AF8DFQ27012625-13043D09-3EBE-46D1-AC93-0E686E25D576Q30480789-DC3D93EA-4D08-4017-9A18-6C74A2608E37Q31016356-49D94CCA-EDDD-4A6A-8CB7-96AE7FF0008AQ33591899-89DB8911-360D-4319-8E67-539FC79EC4A7Q33770577-A9D1175B-B355-4D87-9A89-C306BE51166BQ33783760-278C3D11-72E0-4C2B-B0AE-8BFB7210940FQ34074832-277A9138-924B-459B-BDAF-25C645CA2F71Q34316776-4FF8465C-0691-4017-B7EE-84E42BE2DB93Q34436393-17974A9F-09D9-433B-9B1C-A624BEF3BBEBQ34550155-F94AA8B6-BA77-4E97-9FE7-09C0CB0D04A7Q34957303-3B558423-FE26-4D2B-8D91-B11689002ACCQ35135970-26821FA0-18DA-4C33-A2D6-5EAD077F9853Q35201031-0521F046-9E18-4CEF-A262-0A44E3EFD911Q35204290-83C2E655-8BBA-4D0D-A40E-85311A6C28BBQ35537584-37D6E92E-DF6E-4D14-B92E-B283FDDB1591Q35537629-6B300A8E-7CA9-4096-B9BC-24FEE57A6E0DQ35574022-B47989BA-65E6-4CA0-B8D6-FAD8E4323662Q35627824-D0BADC41-D6F2-40B0-B5B6-BC2E8E61769EQ35695388-D35887BA-7DB0-4355-9125-C24270753ACBQ35747045-21D857C6-E384-4D1F-84FA-A3EB5DA9880FQ35810452-FDF8F090-B265-41E2-97AF-008971AB4C6AQ36040655-31A4A477-6945-41F1-BFB7-515442A3B595Q36288980-4173DD03-4A17-4B14-9399-6E6C7AC4CFBBQ36356295-80FF5A48-5410-4385-A3E1-21CDBB52A68BQ36443665-02961894-63A7-4A56-8C27-FC8E1BED1501Q36642198-321AFAAE-1A3C-4515-AC8A-6CEFD9E82A66Q36792644-2710DBF5-CBDA-4397-97DF-C1554AC8BDF7Q36843717-3BF5AD9E-9ABE-4D1D-B6D7-A6AC705002AC
P2860
Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Inhaled formoterol dry powder ...... obstructive pulmonary disease.
@en
Inhaled formoterol dry powder ...... obstructive pulmonary disease.
@nl
type
label
Inhaled formoterol dry powder ...... obstructive pulmonary disease.
@en
Inhaled formoterol dry powder ...... obstructive pulmonary disease.
@nl
prefLabel
Inhaled formoterol dry powder ...... obstructive pulmonary disease.
@en
Inhaled formoterol dry powder ...... obstructive pulmonary disease.
@nl
P2093
P2860
P1476
Inhaled formoterol dry powder ...... obstructive pulmonary disease.
@en
P2093
Formoterol in Chronic Obstructive Pulmonary Disease I Study Group
G Della Cioppa
L A Greefhorst
M H Thomson
P2860
P304
P356
10.1164/AJRCCM.164.5.2007006
P407
P577
2001-09-01T00:00:00Z